Trial · NCT00923117

Sunitinib to Treat Recurrent Brain Cancer

NCT00923117, Phase 2, Terminated, National Cancer Institute (NCI); results first posted 2013-06-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Sunitinib to Treat Recurrent Brain Cancer. Trials, record NCT00923117. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00923117

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Sunitinib to Treat Recurrent Brain Cancer
NCT number: NCT00923117
Status: Terminated
Phases: Phase 2
Enrollment: 87 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
Interventions: Sutent (sunitinib)
First posted: 2009-06-18
Last updated: 2015-09-30
Results first posted: 2013-06-25
Limitations and caveats: The study was terminated based on results of an interim analysis for futility.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	6-month Progression-free Survival.	6 months	Time between the start of treatment to progression. Progression is defined by the RANO(Response Assessment in Neuro-Oncology) criteria. Progression is defined by any of the following: 25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration.
Secondary	Number of Participants With Adverse Events	7/2/08 -12/6/13	Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	6-month Progression-free Survival.	6 months	63 patients enrolled with glioblastoma multiforme (GBM) (32 Bev naive, 31 Bev resistant) and were evaluated for this outcome measure.	Months	MEDIAN
SECONDARY	Number of Participants With Adverse Events	7/2/08 -12/6/13		Participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
6-month Progression-free Survival.	Bevacizumab Resistant Patients	0.92	95% Confidence Interval 0.89 to 0.92	Months
6-month Progression-free Survival.	Bevacizumab Naive Patients	1.08	95% Confidence Interval 0.92 to 2.47	Months
Number of Participants With Adverse Events	Bevacizumab Resistant Patients	44		Participants
Number of Participants With Adverse Events	Bevacizumab Naive Patients	43		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Bevacizumab Resistant Patients	44
Overall Study	STARTED	Bevacizumab Naive Patients	43
Overall Study	COMPLETED	Bevacizumab Resistant Patients	44
Overall Study	COMPLETED	Bevacizumab Naive Patients	43
Overall Study	NOT COMPLETED	Bevacizumab Resistant Patients	0
Overall Study	NOT COMPLETED	Bevacizumab Naive Patients	0

Source ClinicalTrials.gov

Adverse events284

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhea	Gastrointestinal disorders	Bevacizumab Resistant Patients	13	44	14
other	Diarrhea	Gastrointestinal disorders	Bevacizumab Naive Patients	7	43	11
other	Hypertension	Cardiac disorders	Bevacizumab Resistant Patients	24	44	25
other	Hypertension	Cardiac disorders	Bevacizumab Naive Patients	13	43	18
other	ALT/SGPT (serum glutamic pyruvic transaminase)	Metabolism and nutrition disorders	Bevacizumab Resistant Patients	21	44	25
other	ALT/SGPT (serum glutamic pyruvic transaminase)	Metabolism and nutrition disorders	Bevacizumab Naive Patients	21	43	30
other	AST/SGOT (serum glutamic oxaloacetic transaminase)	Metabolism and nutrition disorders	Bevacizumab Resistant Patients	12	44	16
other	AST/SGOT (serum glutamic oxaloacetic transaminase)	Metabolism and nutrition disorders	Bevacizumab Naive Patients	10	43	10
other	Albumin, serum-low (hypoalbuminemia)	Metabolism and nutrition disorders	Bevacizumab Resistant Patients	20	44	23
other	Albumin, serum-low (hypoalbuminemia)	Metabolism and nutrition disorders	Bevacizumab Naive Patients	19	43	24

1 to 10 of 284Source ClinicalTrials.gov

See all 284 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bevacizumab Resistant Patients
Total, all-cause mortality	Bevacizumab Naive Patients
Total, other adverse events	Bevacizumab Resistant Patients	44	44
Total, other adverse events	Bevacizumab Naive Patients	43	43
Total, serious adverse events	Bevacizumab Resistant Patients	16	44
Total, serious adverse events	Bevacizumab Naive Patients	13	43

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
8931682	BACKGROUND	PubMed
12672281	BACKGROUND	PubMed
17237035	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: Number of Participants With Adverse Events	Trial comparisons
Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00923117

GET https://conductscience.org/api/trials/v1/NCT00923117/events?page=2

API reference For AI assistants